



Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017

May 3, 2017

BOULDER, Colo., May 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2017 and hold a conference call to discuss those results on Wednesday, May 10, 2017. Ron Squarer, Chief Executive Officer, will lead the call.

Date: Wednesday, May 10, 2017
Time: 9:00 a.m. Eastern Time
Toll-Free: (844) 464-3927
Toll: (765) 507-2598
Pass Code: 92608803



Webcast, including Replay and Conference Call Slides: <http://edge.media-server.com/m/p/hgm92o9w>

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to seven drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology), tucatinib (partnered with Cascadian Therapeutics) and ipatasertib (partnered with Roche).

CONTACT: Tricia Haugeo
Array BioPharma Inc.
(303) 386-1193
thaugeo@arraybiopharma.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2017-on-may-10-2017-300450284.html>

SOURCE Array BioPharma